User:Mr. Ibrahem/Delavirdine

Mr. Ibrahem/Delavirdine
Clinical data
Pronunciation	del a' vir deen
Trade names	Rescriptor
Other names	Delavirdine mesylate
AHFS/Drugs.com	Monograph
MedlinePlus	a600034
Pregnancy; category	AU: B3; ;
reverse transcriptase inhibitor (NNRTI)
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Bioavailability	85%
Protein binding	98%
Metabolism	Liver (CYP3A4- and CYP2D6-mediated)
Elimination half-life	5.8 hours
Excretion	Kidney (51%) and fecal (44%)
Identifiers
	IUPAC name N-[2-({4-[3-(propan-2-ylamino)pyridin-2-yl]piperazin-1-yl}carbonyl)-1H-indol-5-yl]methanesulfonamide;
Chemical and physical data
JSmol)	Interactive image;
	SMILES CC(C)Nc1cccnc1N4CCN(C(=O)c3cc2cc(NS(C)(=O)=O)ccc2[nH]3)CC4;
	InChI InChI=1S/C22H28N6O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20/h4-8,13-15,24-26H,9-12H2,1-3H3 ; Key:WHBIGIKBNXZKFE-UHFFFAOYSA-N ;
	(verify)

Delavirdine (DLV), sold under the brand name Rescriptor, is a medication used to treat HIV/AIDS.^[2] It is used together with other HIV medicines; though is not a preferred treatment.^[2] It is taken by mouth, three times per day.^[2]

Common side effects include tiredness, dizziness, headache, and rash.

reverse transcriptase inhibitor (NNRTI).^[2]

Delavirdine was approved for medical use in the United States in 1997.[2] It has been discontinued in the United States as of 2021.^[2] It is not commonly used.^[1]

References

^ ^a ^b ^c ^d "Delavirdine". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 6 May 2021. Retrieved 23 December 2021.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k "Delavirdine Mesylate Monograph for Professionals". Drugs.com. Archived from the original on 15 May 2016. Retrieved 23 December 2021.

[Liv2021-1] "Delavirdine". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 6 May 2021. Retrieved 23 December 2021.

[AHFS2021-2] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k "Delavirdine Mesylate Monograph for Professionals". Drugs.com. Archived from the original on 15 May 2016. Retrieved 23 December 2021.

[1]

[2]